Streetbeat News

HCWB

HCW Biologics Inc.

https://www.hcwbiologics.com

Industry

Biotechnology

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Open

0.86

Mkt cap

27M

Volume

3.8M

High

0.87

P/E Ratio

-0.70

52-wk high

2.52

Low

0.69

Div yield

N/A

52-wk low

0.28

HCW Biologics (NASDAQ:HCWB) reported a Q1 EPS of $(0.20), a 42.86% decrease from $(0.14) YoY, and sales of $1.13M, a 2.59K% increase from $41.88K YoY.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 9:01 pm

HCW Biologics announced that due to a default issue, its financial statements for the year ended December 31, 2023, need to be restated and should no longer be relied upon, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:02 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. PaxMedica led the gainers with a 104.2% increase, while Motus GI Holdings experienced the largest drop among the losers, falling 26.1%. The movements reflect notable volatility in the healthcare sector, with companies ranging from biotech to pharmaceuticals experiencing shifts in their stock prices.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 12:09 pm

HCW Biologics has expressed concerns about its financial stability, indicating substantial doubt unless it can secure additional financing. The company plans to alleviate these concerns by adjusting its strategic and operating plans, which include reducing the number of investigative studies and Phase 2 clinical trials, cutting salaries and other expenses, and limiting cash used to reduce accounts payable among other adjustments.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 8:19 pm

HCW Biologics reported Q4 2023 earnings with a GAAP EPS of $(0.15), missing the $(0.14) estimate, but their sales of $1.341M exceeded the $900K estimate. This represents a slight decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 8:17 pm

HCW Biologics terminated its credit agreement with Prime Capital Ventures due to repeated funding delays and related concerns, as permitted by the agreement terms.

Portfolio Pulse from Charles Gross

January 12, 2024 | 12:33 pm

Anavex Life Sciences Corp. (AVXL) shares dropped by 10% after reporting a Q4 net loss of $10.1 million, or 12 cents per share, compared to a net loss of $14.3 million, or 18 cents per share, in the same period last year. Other stocks experienced significant movements in Monday's mid-day session, with notable gainers including RedHill Biopharma Ltd. (RDHL), Biodexa Pharmaceuticals Plc (BDRX), and Tharimmune, Inc. (THAR), among others. Losers included 10X Capital Venture Acquisition Corp. II (VCXA), BioNexus Gene Lab Corp. (BGLC), and HCW Biologics Inc. (HCWB). Affirm Holdings, Inc. (AFRM) saw a jump of 13.7% following positive 'buy now, pay later' predictions for Cyber Monday.

Portfolio Pulse from Lisa Levin

November 27, 2023 | 6:41 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. Senti Biosciences, MSP Recovery, HCW Biologics, Tempest Therapeutics, TransCode Therapeutics, and Nemaura Medical saw increases in their share prices, while Avalo Therapeutics, Axcella Health, Eiger BioPharmaceuticals, ENDRA Life Sciences, Jin Medical International, and Synlogic experienced decreases.

Portfolio Pulse from Benzinga Insights

September 14, 2023 | 9:31 pm

HCW Biologics has received a US patent for a method of promoting the activation and proliferation of natural killer cells, known as the company's 'Prime and Expand' method.

Portfolio Pulse from Benzinga Newsdesk

August 31, 2023 | 11:16 am

HCW Biologics reported holding $17.4M in cash, cash equivalents, and U.S. Treasury bills of short duration. This is expected to fund the company's operations into Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:19 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.